Executive Summary Biopure Corporation was established in 1984 and is a privately owned pharmaceutical firm. They are trying to launch two new products: Hemopure (human market) and Oxyglobin (veterinary market). They are the only company aggressively engaged in the development of blood substitutes for the vet market. Biopure has invested $200M in the development of said blood substitutes. They currently don’t have any revenues with little to no debt and financing of $50M to support these operations
Premium Health care Net present value Medicine
Carl Rausch President and CEO of Biopure Corporation FROM: Hoang‚ Ann and Mishra‚ Ravi RE: Whether and When to Launch Oxyglobin Biopure needs to determine the best course of action to launch two new products‚ Oxyglobin a blood substitute for the veterinary market and Hemopure a blood substitute for the human market. Oxyglobin has been approved for commercial use and is ready for launch while Hemopure is expected to be FDA approved within two years. Biopure needs to decide whether and when
Premium Blood Blood transfusion Marketing
+ Biopure Corporation Case Analysis Back Bay Xue Yang + Agenda 1. Current Situation 2. SWOT Analysis 3. Quantitative Analysis 4. Recommendations + Current SituationBiopure Corporation The main objectives of Biopure Corporation is blood substitutes development There are 2 products: Oxyglobin and Hemopure. Oxyglobin is targeting at veterinary market and Hemopure is targeting at human market The company has spent $200 million on R&D of Hemopure Oxyglobin has already approved
Premium Variable cost Blood Marketing
MARKET POTENTIAL ANALYSIS OF COMMERCIAL PACKED BHARAT LPG A Summer internship report submitted in partial fulfilment of the Degree of Master of Business Administration of Thiagarajar School of Management‚ Madurai By P.NALLATHAMBI Register No – 1111084 Under the guidance of Mr. Ramanuja Chari‚ Territory Manager (LPG) & CPIO‚ BPC Ltd Prof. P. Mutharasi‚ Faculty‚ TSM‚ Madurai [pic] Thiagarajar School of Management (Affiliated to Madurai Kamaraj University) Madurai
Premium Petroleum
Executive Summary Biopure Corporation is one of the pioneers in the development of oxygen therapeutics using “Hemoglobin”‚ a new class of pharmaceuticals that deliver oxygen to the body’s tissues. Biopure developed two main products under years of research and development‚ “Hemopure” for human use‚ and “Oxyglobin” for animal veterinary use‚ both represented a new oxygen based treatment approach for managing patients’ oxygen requirements. Biopure’s two products differ from other blood substitute
Free Blood Blood transfusion
recommendation that Biopure should immediately launch Oxyglobin. The reasons for this decision are as followed: Obtaining the Monopoly on blood substitutes - If Biopure waits to launch Oxyglobin they will miss a prime opportunity to control the blood substitute market‚ especially the animal market. As mentioned in the case‚ Biopure’s competitors have yet to launch their products. Furthermore‚ Baxter International and Northfield Laboratories do not have an animal substitute for Biopure to compete with1
Premium Blood transfusion Blood Marketing
·444· Proceedings of the 7th International Conference on Innovation & Management Analyzing of Potential Market of China for Ethiopian Coffee Eskinder Asfaw Bantiwalu‚ Asfaw Yilma Demisse School of Management‚ Wuhan University of Technology‚ Wuhan‚ P.R.China‚ 430070 (E-mail: eskinder_2001@yahoo.com‚ Asfity333@yahoo.com) Abstract After analyzing the opportunities and challenges of Chinese market by using secondary data‚ this paper finds that the population of China (1.3 billion)‚ the increasing
Premium Coffee Coffee preparation Ethiopia
Q1. Should Biopure launch Oxyglobin? Why? Support your arguments with quantitative analysis (ie. calc. of market potential). We believe that Biopure should launch Oxyglobin now. First of all‚ the potential market demand is huge. While current annual demand is 354‚750 units (95% primary care practices x 17 units canine blood/primary care practice + 5% specialty care practices x 150 units canine blood/specialty care practice)i accounting for only 2.5% of the cases‚ potential market demand including
Premium Blood Marketing Blood transfusion
the major companies in this industry is Gerber Foods‚ a subsidiary of Novartis Because Gerber products target prenatal to toddler age children‚ brand loyalty can be created at an early stage of a child’s life. It is important‚ however‚ for Gerber to market their full range of products early enough to create such a loyalty. According to a study conducted by the Agri-Food Trade Services‚ sales of Organic based foods have increased yearly over 20%. In 2003‚ the total organic food sales were estimated
Premium Organic food Sustainable agriculture Baby food
Insurance Industry 40 Life Insurance industry 41 Aggregation of Long Term Savings 42 Spread of financial services in rural Areas 43 Long term funds for infrastructure Development of Capital Markets/Economic Growth 44 Employment generation 45 Special Features 46 Growth Potential 47 Phase of transition 47 Chapter 4:Company Profile 49 Management 51 Area of Business 56 KMOM progress till date 65 KMOM-the partnership and Lineage 66 Products 69 Hierarchy of
Premium Insurance Life insurance Financial services